A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study
to Evaluate the Safety, Tolerability, and Pharmacokinetics of
Topically Applied INM-755 Cream in Healthy Volunteers and to
Study Suction Blisters as a Wound Healing Model

1. Male or female subject between 18 and 45 years of age inclusive at the time of consent.
2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive
3. Subject is in good general health, according to the investigator’s judgment based on vital signs, medical history, physical examination, and laboratory tests performed.
4. Contraception:
a. Male participants:
i. A male participant who agrees to follow the contraceptive guidance during their participation in this study from at least 90 days before Day 1 until at least 90 days after the last study product administration.
b. Female participants:
i. A female participant is eligible to participate if she is not pregnant, does not plan to become pregnant during the study, not breastfeeding, and at least 1 of the following conditions applies:
1. Not a woman of child-bearing potential (WOCBP)
OR
2. A WOCBP who agrees to follow the contraceptive guidance during
their participation in this study from at least 90 days before Day 1 until
at least 90 days after the last study product administration.
5. Female subject has had a negative urine pregnancy test at screening and at Day 1 before dosing.
6. Subject is willing to participate and is capable of giving informed consent.
7. Subjects must be willing to comply with all study procedures, have the ability to communicate well with the investigator in the Dutch language and must be available for the duration of the study.
8. Subject has sufficient application area of healthy intact skin of the back.

1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
3. Subject has presence of or has a history of atopic dermatitis or psoriasis.
4. Any known allergy or hypersensitivity to medical adhesives (e.g., Tegaderm®) used in this study or any component of the study product (e.g., Poloxamers, Lecithin, Isopropyl Palmitate).
5. Subject has presence of any tattoos, scratches, open sores, excessive hair, or skin damages in the target treatment area(s) that, in the opinion of the investigator, may interfere with study evaluations.
6. Subject has a Fitzpatrick’s Skin Phototype ≥4.
7. Subject is known to have immune deficiency or is immunocompromised.
8. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).
9. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
10. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
11. Subject has any clinically significant medical condition or physical, laboratory, ECG, or vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere
with interpretation of study results.
12. Subject has used any systemic treatment that could be immunosuppressive (including oral corticosteroids, oral retinoids, immunosuppressive medication, methotrexate, cyclosporine, or
apremilast) within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
13. Subject has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (except on application areas) and
protective apparel are recommended when sun exposure cannot be avoided.
14. Subject has received laser treatment, electrolysis on the application areas within 4 weeks prior to Day 1 or is planning to during the study period.
15. Subject has shaved the application area 72 hours prior to Day 1,or is planning to do so during the study period.
16. Subject has used cannabis or any cannabinoid products within 12 weeks prior to Day 1.
17. Subject has used any medication known to impair alertness and/or ability to detect discomfort within 1 week prior to Day 1.
18. Subject has used a topical administrated treatment on the targeted application area(s) within 1 week prior to Day 1.
19. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
20. Subject has a positive screen result for drug of abuse at screening and at Day 1 before dosing.
21. Subject is unwilling to avoid contact with water on the treatment condition area(s) during the treatment period.
22. Subject is requiring frequent use of pain medication (e.g., acetaminophen or NSAIDs) to relieve chronic pain (e.g., frequent headaches, migraines, dysmenorrhea, arthritis).
23. Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites.
24. Subject has taken anticoagulant medication, such as heparin, low molecular weight (LMW)-heparin, warfarin, anti-platelets (except low-dose aspirin ≤81 mg which will be allowed), within 2 weeks prior to Day 1, or has a contraindication to skin biopsies.
25. Loss or donation of blood over 500 mL within 12 weeks prior to screening
26. Participation in any marketed or investigational drug or device study within 12 weeks or 5 half-lives (whichever is longer) prior to first dosing.
27. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.